The Evoke Spinal Cord Stimulator (SCS) System (Evoke® System) is an FDA-approved device that is used to manage long lasting, severe pain that is not relieved by typical medical treatments.

This research registry is being conducted to collect data from patients treated with a SCS device in order to determine how the device impacts their chronic pain condition.

Specifically, the study aims to:

• Evaluate data collected from the SCS system on how well the system is working.
• Evaluate the feasibility of programming the SCS system independently without external assistance.
• Evaluate changes in physical function, fatigue, pain interference, mood, sleep, daily activities, pain control, and overall satisfaction with the device.

Inclusion Criteria:

• Subject is not pregnant and 18 years of age or older at the time of enrollment.
• Subject has a minimum NRS score of 6 or higher (where 10 indicates the worst imaginable pain) in primary area of pain at baseline.
• Subject is planning to have a temporary trial with the Evoke® System to aid in the management of chronic intractable pain of the trunk and/or limbs.
• Subject is willing to program the Evoke® System using EVA™ under the supervision of the study investigator or Qualified Health Professional.
• Subject is being trialed with a neurostimulation system for the first time.
• Subject is able to read and understand English.
• Subject is capable of subjective evaluation; subject must be able to describe and rate his/her pain levels.
• Subject is willing and capable of giving informed consent.
• Subject is willing and able to comply with study-related requirements, procedures, and visits.
• Subject has adequate cognitive ability to use a patient programmer and recharger as determined by the Investigator.

Exclusion Criteria:

- There are no exclusion criteria for this study.

Subjects with chronic, intractable focal pain of the trunk and/or limbs will be screened for participation in this study. Subjects who provide informed consent and meet the eligibility criteria will be enrolled and will undergo a trial procedure. Following the trial phase subjects may receive a permanent implant. Enrollment will continue until 30 subjects receive a permanent implant. We estimate that up to 40 subjects will be enrolled in this registry.